Scientists
  • ● Faculty and Staff
Name:
Xing-Jie Liang
Education:
Ph.D
Positions:
Deputy Director of the Laboratory of Biological Effects of Nanomaterials and Nanosafety
Academic title:
Professor
Postal Code:
100190
Subject categories:
Nanomedicine
Mailing Address:
No.11,Beiyitiao Zhongguancun Beijing,china
E-mail:
liangxj(AT)nanoctr.cn

Resume:

  Dr. Xing-Jie Liang got his Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and Lab Chief of Laboratory of Controllable Nanopharmaceuticals, National Center for Nanoscience and Technology of China. He is also leading a group on nanopharmaceuticals at the CAS Center for Excellence in Nanoscience. Dr. Xing-Jie Liang is a founder member of International Society of Nanomedicine, member of American Association for Cancer Research, and member of American Society of Cell Biology. Dr. Xing-Jie Liang is also deputy director of Nanomedicine and Nanopharmaceuticals Committee at Society of Nanobiology and Nanomedicine and Deputy Director of Nanomedicinal Materials committee of Chinese Society of Biomaterials. 

    

  Dr. Xing-Jie Liang is current deputy Editor-in-Chief of Biophysics Reports and Associate Editor of Biomaterials, Advisory Board Member of ACS Nano. He is also current editorial board member of current nanoscience, Biomaterials Research,Theranosticsand guest editor of Biotechnology Advances. 

    

  The current researches include three topics ongoing in the laboratory.  

  1.Nanotherapy: FDA approved materials developed with nanotechnologies to improve the bioavailability and therapeutic efficancy as well as to decrease toxicity of chemocompounds or bio-drugs (genes or proteins) by targeted delivery and controllable release;  

  2.Nanoimmunology: Unique immunological responses of nanomaterials and nanoadjuvants by different administration in vivo:  

  3.Nanobiotechnology: Nanostructures to solve the medicinal or pharmaceutical toughest problems (MDR, stem cells development etc): 

  4.Nanoplatform: Nanoscale DDS for Chemo-/Gene-Therapy; Nano-AIE for Pharmadynamic/Kinetic evaluation.     

  In addition, another topic on nanoimaging is another interested field in his group.  

  5.Nanoimaging and Nanodiagnosis:  Nanopharmaceuticals ADMET in vivo by various techniques (Nano SPECT/CT, Acoustic ultrasound, In vivo Imaging, MRI, Bio-TEM etc)    

    His researches are to develop nanopharmaceuticals for clinical trials and transfer FDA-certified licenses to pharmaceutical companies for production. This mission is from his interests in elucidating mechanisms to improve nanomedicinal bioavailability by nanotechnology in vivo, and developing novel strategies to increase therapeutic effect on cancers and infectious diseases. Improved drug delivery efficiency for prevention/treatment of AIDS and cancers are under investigation in Dr. Liang's lab based on understanding of basic physio-chemical and biological processes of nanodrugs. Most protocols are employed for delivering therapeutic molecules to actively target cells or tissues in vivo to enhance drug safety and efficacy. Dr. Liang’s current research activities include: Nanotherapeutics for diseases treatment; Nanoparticle interactions with biological membranes; Nanotechnology to circumvent multidrug resistance of cancer; Nanobiomedicine and nanosafety; Nanotechnology to improve the vaccine immunogenicity; Nanomaterials imaging in vitro and in vivo.

Direction:

nanomedicine and nanopharmaceuticals 

Achievements:

2004 2005 and 2006 "Fellows Award for Research Excellence" National Institute of Health, USA. “Special Government Allowances” by Department of State, 2011; “National Distinguished Young Scholars” by NSFC; “Young Pharmaceutics Scholar” by CPA, 2012; “Outstanding Research Award” to hundred elite researcher of CAS, 2013; “Natural Science Research Award” by HeBei Province Bureau of Science and Technology, 2014; and “Inspection Improve Award” by General Administration of Quality Supervision, Inspection and Quarantine of the People’s Republic of China, 2014.Adjuvant Professor of Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Biomedical Engineering.

Article:

  1.Xue X , Yang J, He Y, Wang L, Liu P, Yu L, Bi G, Zhu M, Liu Y, Xiang R, Yang T, Fan X, Wang X, Qi J., Zhang H., Wei T., Cui W., Ge G. , Xi Z*., Wu C*., Liang XJ*. Aggregated single - walled carbon nanotubes attenuate the behavioral and neurochemical effects of methamphetamine in mice. Nature Nanotechnology 2016. DOI: 10.1038/NNANO.2016.23. 

  2.Tuguntaev R, Okeke C, Xu J, Li C,* Wang PC and Liang XJ*. Nanoscale polymersomes as anti-cancer drug carriers applied for pharmaceutical delivery. Current Pharmaceutical Design. 2016. accepted 

  3.Zhuang X; Ma X*; Xue X; Jiang Q; Song L; Dai L; Zhang C; Jin S; Yang K; Ding B; Wang P; Liang XJ*. A Photosensitizer-loaded DNA Origami Nanosystem for Photodynamic Therapy. ACS Nano. 2016. revised.  

  4.Ma X, Gong N, Zhong L, Liang XJ*. Future of Nanotherapeutics: Targeting the Cellular Sub-organelles. Biomaterials. 2016. revised 

  5.Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X*; Liang XJ*. Multifunctional Aptamer-based Nanoparticles for Targeted Drug Delivery to Circumvent Cancer Resistance. Biomaterials. 2016. revised 

  6.Zhao J, Liu J, Wei T, Ma X, Huo S, Zhang C, Zhang Y, Duan X* and Liang XJ*. Quercetin-loaded nanomicelles to circumvent human castration-resistant prostate cancer in vitro and in vivo. Nanoscale. 2016, DOI: 10.1039/C5NR08966B 

  7.Xue X, Xu J., Wang PC, Liang XJ*. Subcellular Behaviours Evaluation of Nanopharmaceuticals with Aggregation-Induced Emission Molecules. Journal of Material Chemistry C. 2016, DOI: 10.1039/C5TC03651H 

  8.Chen S, Yang K, Tuguntaev RG, Mozhi A, Zhang J*, Liang XJ*.Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance. Nanomedicine 2016. DOI10.1016/j.nano.2015.10.020. 

  9.Jiang Y, Huo S, Hardie J, Liang XJ and Rotello VM. Progress and perspective of inorganic nanoparticles based siRNA delivery system. Expert Opinion on Drug Delivery. 2016. DOI:10.1517/17425247.2016.1134486.   

  10.Li H, Lee T, Dziubla T, Pi F, Guo S, Xu J, Li C, Haque F, Liang XJ and Guo P. RNA as a Stable Polymer to Build Controllable and Defined Nanostructures for Material and Biomedical Applications. Nano Today. 2015. 10: 631-655. 

  11.Gong N, Chen S, Jin S, Zhang J, Wang PC, Liang XJ*.Effects of the physicochemical properties of gold nanostructures on cellular internalization. Regenerative Biomaterials. 2015.273-280. 

  12.Xue X, Zhao Y, Zhang X, Zhang C, Kumar A, Zhang X, Zou G, Wang PC, Zhang J, Liang XJ*. Phenylboronic Acid Functionalized Magnetic Nanoparticles for One-step Saccharides Enrichment and Mass Spectrometry Analysis. Biophysics Report. 2015. 1(2):61-70.  

  13.Wang Y, Che J, Zheng Y, Chen F, Jin S, Gong N, Zhong L, Xu J, Zhao Y* and Liang XJ*. Multi-stable fluorescent silica nanoparticles obtained from in situ doping with aggregation-induced emission molecules. Journal of Materials Chemistry B. 2015, 3, 8775 – 8781. 

  14.Hao X, Hu X, Zhang C, Chen S, Li Z, Yang X, Liu H, Jia G *, Liu D, Ge K, Liang XJ*, Zhang J *. Hybrid Mesoporous Silica-Based Drug Carrier Nanostructures with Improved Degradability by Hydroxylapatite. ACS Nano. 2015. 27, 9(10):9614-9625.   

  15.Jiang Y, Huo S, Hou S, Mizuhara T, Moyano DF, Duncan B, Liang XJ and Rotello VM. The Interplay of Size and Surface Functionality on the Cellular Uptake of Sub-10 nm Gold Nanoparticles. ACS Nano. 2015. 27, 9(10):9986-9993.  

  16.Yang K, Li S, Jin S, Xue X, Zhang T, Zhang C, Xu J and Liang XJ*. Micelle-like Luminescent Nanoparticles as a Visible Gene Delivery System with Reduced Toxicity. Journal of Materials Chemistry B, 2015, 3: 8394 – 8400. 

  17.Liu Y, Zhang D, Qiao ZY, Qi GB, Liang XJ, Chen XG, Wang H. A Peptide-Network Weaved Nanoplatform with Tumor Microenvironment Responsiveness and Deep Tissue Penetration Capability for Cancer Therapy. Adv Mater. 2015.27(34): 5034-5042.  

  18.Zhao Y; Chen F; Pan Y; Li Z; Xue X; Okeke C; Wang Y; Li C; Peng L; Wang P; Ma X*; Liang XJ*. Nanodrug Formed by Co-assembling of Dual Anticancer Drugs to Inhibit Cancer Cell Drug Resistence. ACS Applied Materials & Interfaces. 2015. 7(34):19295-19305. 

  19.Huang Y, Wang X, Huang W, Cheng Q, Zheng S, Guo S, Cao H, Liang XJ, Du Q and Liang Z. Systemic Administration of siRNA via cRGD-containing Peptide. Scientific Reports. 2015. 5: 12458. 

  20.Zhang J, Li S, An F, Liu J, Jin S, Zhang J, Wang PC, Zhang X, Lee CS and Liang XJ*. Self-carried Curcumin Nanoparticles for In vitro and In vivo Cancer Therapy with Real-time Monitoring of Drug Release. Nanoscale. 2015. 7(32):13503-13510. 

  21.Chen F, Zhao Y, Pan Y, Xue X, Zhang X, Anil K, Liang XJ*.Synergistically Enhanced Therapeutic Effect of a Carrier-Free HCPT/DOX Nanodrug on Breast Cancer Cells through Improved Cellular Drug Accumulation. Molecular Pharmaceuticals. 2015. 12:2237-2244. 

  22.Xue X, Jin S, Zhang C, Yang K, Huo S, Chen F, Zou G and Liang XJ*. A Probe-Inspired Nano-Prodrug with Dual-Color Fluorogenic Property Reveals Spatiotemporal Drug Release in Living Cells. ACS Nano. 2015. 24; 9(3):2729-2739. 

  23.Li S, Zhang C, Cao W, Ma B, Ma X, Jin S, Zhang J, Wang PC, Li F and Liang XJ*. Anchoring Effects of Surface Chemistry on Gold Nanorods: Modulates Autophagy. Journal of Materials Chemistry B. 2015. 3, 3324 – 3330. 

  24.Wei T, Chen C, Liu J, Liu C, Posocco P, Liu X, Cheng Q, Huo S, Liang Z, Fermeglia M, Pricl S, Liang XJ*, Rocchi P, Ling Peng*. Anticancer drug nanomicells formed by self-assembling amphiphilic dendrimers to combat cancer drug resistence. Proc Natl Acad Sci U S A. 2015. 112(10): 2978-2983. 

  25.Yang J, Li Y, Jin S, Xu J, Wang PC, Liang XJ*, Zhang X. Engineered biomaterials for development of nucleic acid vaccines. Biomaterials Research. 2015.19:5.1-9.  

  26.Zhang T, Song X; Zhang L; Zhang C, Cao W, Jin S, Wang C; Tian J; Xing J* and Liang XJ*.Modified Bovine Serum Albumin as an Effective Charge-reversal Platform for Simultaneously Improving Transfection Efficiency and Biocompatibility of Polyplexes. Journal of Material Chemistry B. 2015. 3, 4698-4706 

  27.Xiang Z, zhang T, Song, X, Zhang L, Zhang C, Jin S, Xing J, Liang XJ*. Structural impact of graft and block copolyme rs based on poly(N-vinylpyrrolidone) and poly(2-dimethylaminoethyl methacrylate) in gene delivery. Journal of Materials Chemistry B.  2015, 3: 4027-4035 

  28.Song Y, Zhang T, Song X, Zhang L, Zhang C, Xing J and Liang XJ*. Polycations with excellent gene transfection ability based on PVP-g-PDMAEMA with random coil and micelle structures as non-viral gene vectors. Journal of Materials Chemistry B.  2015, 3: 911-918. 

  29.Zhang C, Li Y, Xue X, Chu P, Liu C, Yang K, Jiang Y, Chen W, Zou G, Liang XJ*. A smart pH-switchable luminescent hydrogel. Chem Commun. 2015. 51(20):4168-4171. (BACK COVER) 

  30.Zhang J, Li C, Zhang X, Huo S, Jin S, An F, Wang X, Xue X, Okeke CI , Duan G, Fengguang Guo, Zhang X, Hao J, Wang PC, Zhang J, Liang XJ*. In vivo tumor-targeted dual-modal fluorescence/CT imaging using a nanoprobe co-loaded with an aggregation-induced emission dye and gold nanoparticles. Biomaterials. 2015.(4) 103-111. 

  31.Zhang C, Xue X, Luo Q, Li Y, Yang K, Zhuang X, Jiang Y, Zhang J, Liu J, Zou G and Liang XJ*. Self-Assembled Peptide Nanofibers Designed as Biological Enzymes for Catalyzing Ester Hydrolysis. ACS Nano. 2014. 25;8(11):11715-23 

  32.Huang Y, Wei T, Yu J, Hou Y, Cai K*, Liang XJ*.  Multifunctional Metal Rattle-Type Nanocarriers for MRI-Guided Photothermal Cancer Therapy.  Molecular Pharmaceutics 2014. 11(10):3386-3394.  

  33.Xue X, Wang L, Sato Y, Jiang Y, Berg M, Yang DS, Nixon R, Liang XJ*.  Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Lett. 2014 14(9):5110-5117. 

  34.Huo S, Jin S, Ma X, Xue X, Yang K, Wang PC., Zhang J, Hu Z and Liang XJ*. Ultra-small Gold Nanoparticles as Carriers for Nucleus-based Gene Therapy Due to Size-dependent Nuclear Entry. ACS nano. 2014. 24;8(6):5852-5862. 

  35.Xing-Jie Liang. Nanotechnology and Cancer Nanomedicine. Biotechnology Advances 2014.32(4): 665. (editorial comments) 

  36.Liu J, Huang Y, Kumar A, Tan A, Jin J, Mozhi A, Liang XJ*. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnology Advances 2014.32(4): 693-710. 

  37. Xue X, Hall M, Zhang Q, Wang P, Gotteman MM, Liang XJ *. Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein. ACS Nano. 2013. 23;7(12):10452-10464. 

  38.Xue X, Zhao Y, Dai L, Zhang X, Hao X, Huo S, Liu J, Liu C, Kumar A, Zou,G* Liang XJ*. Spatiotemporal Drug Release Visualized Through a Drug Delivery System with Tunable Aggregation-Induced Emission. Advanced Materials. 2014. 26(5):712-717 

  39.Han L.; Zhao J.; Liu J.; Duan X.; Wei Y.; Liang XJ*. A universal gene carrier platform for treatment of human prostatic carcinoma by p53 transfection. Biomaterials. 2014 35(9):3110-3120.  

  40.Li Y,  Cheng Q, Jiang Q, Huang Y, Liu H, Zhao Y, Cao W, Ma G, Dai F,  Liang XJ*, Liang Z, Zhang X*. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine - polycarboxybetaine lipid for systemic delivery of siRNA. Journal of Controlled Release. 2014,176: 28:104–114. 

  41.Sun Y, Cao W, Li S, Jin S, Hu K, Hu L, HuangY, GaoX, Wu Y*, Liang XJ*. Ultrabright and multicolorful fluorescence of Amphiphilic Polyethyleneimine polymerdots for efficiently combined imaging and therapy. Scientific Reports 2013. 3:3036. 

  42.Kumar A, Chen F, Mozhi A, Zhang X, Zhao Y, Xue X, Hao Y, Zhang X, Wang PC, Liang XJ*. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale. 2013, 5 (18), 8307 – 8325. 

  43.Wei T, Liu J, Ma H, ChengQ, Huang Y, Zhao J, Huo S, Xue X, Liang Z, Liang XJ *. Functionalized nanoscale micelles improve the drug delivery for cancer in vitro and in vivo. Nano Letter. 2013. 13(6):2528-2534. 

  44.Kumar A, Zhang X, Liang, X.J*. Gold Nanoparticles: Emerging Paradigm for Targeted Drug Delivery System. Biotechnology Advances. 2013 (31):593-606. 

  45.Gil P, Aberasturi D, Wulf V, Pelaz B, Pino P, Zhao Y, Fuente J, Larramendi, Teófilo Rojo I, Liang, X.J, Parak W. The challenge to relate physico-chemical properties of colloidal nanoparticles to their cytotoxicity.  Accounts of Chemical Research. 2013.46(3):743-749. 

  46.Jia L, Lu Y, Shao J, Liang XJ, Xu Y. Nanoproteomics: a new spout from emerging links between nanotechnology and proteomics. Trends in Biotechnology, 2013. Feb 31(2): 99-107. 

  47.Huo S, Ma H, Huang K, Liu J, Wei T, Jin S, Zhang J, He S and Liang, X.J*. Superior penetration and retention behavior of 50nm gold nanoparticles in tumor. Cancer Research, 2013 73:319-330. 

  48.Hua D, Zhang X, Zou G, Kumar A, Zhang X and Liang, X.J*. Long genomic DNA amplicons adsorption onto unmodified gold nanoparticles for colorimetric detection of Bacillus anthracis. Chemical Communication. 2013, 49(1): 51-53.  

  49.Ma X, Zhang L, Wang L, Xue X, Sun J, Wu Y, Zou G, Wu X, Wang P, Wamer W, Yin J, Zheng K, Liang, X.J*. Single-walled Carbon Nanotubes Alter Cytochrome C Electron Transfer and Modulate Mitochondrial Function. ACS Nano, 2012. 21;6(12):10486-96 

  50.Han L, Zhao J, Zhang X, Cao W, Hua X, Zou G, Duan X, Liang, X.J*. Simple charge-reversal polymer assembly nanosystem with good biocompatibility for enhanced siRNA delivery and silencing. ACS Nano, 2012. 28; 6(8):7340-51. 

  51.Huang Y, He S, Cao W, Cai K and Liang, X.J*. Biomedical nanomaterials for imaging-guided cancer therapy. Nanoscale. 2012, 4 (20), 6135 – 6149. 

  52.Jiang Q, Song C, Nangreave J, Liu X, Lin L, Qiu D, Wang Z, Zou G, Liang, X.J, Yan H, Ding B. DNA Origami as a Carrier for Circumvention of Drug Resistance. JACS. 2012. 134 (32), pp 13396–13403. 

  53.Huang K, Ma H, Liu J, Huo S, Kumar A, Wei T, Zhang X, Jin S, Gan Y, Wang P, He S, Zhang Xand Liang, X.J*. Size-Dependent Localization and Penetration of Ultrasmall Gold Nanoparticles in Cancer Cells, Multicellular Spheroids, and Tumors in vivo. ACS Nano. 2012. 6 (5), 4483–4493. Commented on News and Views.  Nanomedicine (2012) 7(7), 945–948. 

  54.Zhang X, Wu D, Shen X, Chen J, Sun Y, Liu P, Liang, X.J*. Size-dependent radiosensitization of PEG-coated gold nanoparticles for cancer radiation therapy. Biomaterials. 2012. 33(27):6408-19.   

  55.Liu, J, Ma, H., Wei, T. and Liang, X.J*.. CO2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells. Chemical Communication. 2012. 48, 4869–4871  

  56.Ma, H, Jiang, Q., Han, S.Y., Wu, Y., Li T., Wang D., Gan, Y.L., Zou, G.Y.*, and Liang, X.J.*. Multicellular Tumor spheroids (MCTSs) as an in vivo-like model for 3D Imaging of Chemotherapeutics and Nano Materials Penetration. Molecular Imaging, 2012. 11(6): 487-98. 

  57.Liu Z and Liang, X.J*. Nano-Carbons as Theronostics.. Theranostic. 2012, 2(3): 235-237. (Editorial comment) 

  58.Kumar, A., Ma, H., Zhang, X., Huang, K., Jin, S.B., Liu, J., Wei, T., Cao, W.P., Liang, X.J*. Ultra-Small Gold Nanoparticles Fabricated with Therapeutic and Targeted Peptides for Cancer Treatment. Biomaterials 2012. 33(4): 1180-1189. 

  59.Xue, X., You, S., Zhang, Q., Wu, Y.,  Zou, G.Z., Wang, P.C., Zhao, Y., Xu, Y., Jia, L., Zhang, X., Liang, X.J*. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction. Molecular Pharmaceutics, 2012, 9 (3): 634−644. 

  60.Deng, H., Xu, Y., Liu, Y.H., Che, Z.J., Guo, H.L., Shan, S., Sun, Y., Liu, X., Huang, K., Ma, X.W., Wu, Y. and Liang, X.J*. Gold nanoparticles with asymmetric polymerase chain reaction for rapid colorimetric detection of DNA sequence. 2011. Analytical Chemistry, 2012, 2012, 84 (3): 1253–1258. 

  61.Ma, X.W., Wu, Y., Jin, S.B., Tian.Y., Zhang, X.N., Zhao.Y., Yu, L. and Liang, X.J*. Gold Nanoparticles Induce Autophagosome Accumulation through Size-Dependent Nanoparticle Uptake and Lysosome Impairment. ACS Nano. 2011. 5 (11):  8629–8639. 

  62.Ma, X.W., Zhao, Y., Liang, X.J*. Theranostic Nanoparticles engineered for Clinic and Pharmaceutics. Accounts of Chemical Research. 2011. 44(10): 1114–1122.  

  63.Guo, S.T., Huang, Y., Wei, T., Wang, W.D., Wang, W.W., Lin, D., Zhang, X., Kumar, A., Du, Q., Xing, J., Deng, L., Liang, Z., Wang, P., Dong A., and Liang, X.J.* Amphiphilic and Biodegradable Methoxy Polyethylene glycol-block-(polycaprolactone-graft-poly (2-(dimethylamino)ethyl methacrylate)) as an Effective Gene Carrier. Biomaterials, 2011, 32: 879-889. 

  64.Guo, S.T., Huang, Y., Jiang, Q., Sun, Y., Deng, L., Liang, Z., Du, Q., Xing, J., Zhao, Y., Wang, P., Dong A., and Liang, X.J.*. Enhanced Gene Delivery and siRNA Silencing by Gold Nanoparticles Coated with Charge-reversal Polyelectrolyte. ACS Nano. 2010. 4(9): 5505-5511.  

  65.Liang, X.J. *, Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P. C., Zhao, Y., Gao, X., Sun, B., Chen, C., Xing, G., Shen, D., Gottesman, M. M., Wu, Y., Yin, J.J., Jia, L. Metallofullerene Nanoparticles Circumvent Tumor Resistance to Cisplatin by Reactivating Endocytosis.  Proc Natl Acad Sci U S A. 2010. 107(16):7449-7454. 

  66.Ma, X.W., Wang, D., Wu, Y., Ho, RJY, Jia, L., Guo, P., Hu, L., Xing, G., Zeng, Y., Liang, X.J*. AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology. AAPS J. 2010, 12(3):272-278. 

  67.Xing, J, Deng, L, Guo, S, Dong, A, and Liang, X.J*.  Polycationic Nanoparticles as Nonviral Vectors Employed for Gene Therapy In Vivo. Mini-Reviews in Medicinal Chemistry. 2010, 10(2):126-37.  

  68.Tan, J.J., Cong, X.J., Hu, L.M., Wang, C.X., Jia, L and Liang, X.J*. Therapeutic Strategies Underpinning the Development of Novel Techniques for the Treatment of HIV Infection. Drug Discovery Today. 2010. 15(5): 186-197.  

  69.Yin, JJ., Lao, F., Meng, J., Fu, PP., Zhao, YL, Xing G, Gao X, Sun, B, Wang, PC., Chen, C, Liang, XJ*. Inhibition of Tumor Growth by Polyhydroxylated Endohedral Metallofullerenol Nanoparticles Optimized as Reactive Oxygen Species Scavenger. Molecular Pharmacology. 2008. 74: 1132-1140.  

  回国工作前的代表性文章: 

  70.Liang, X. J.*, Shen, D.W., Yin, J.J., Aszalos, A., and Gottesman, M. M. SIRT1 contributes to cisplatin resistance in cancer cells by altering mitochondrial metabolism.  Molecular Cancer Research. 2008, 6(9):1499-1506. 

  71.Liang, X.J., Choi, Y., Sackett, D.L. and Park, J.K.  Inhibition of stathmin enhances CCNU blocking glioma cell migration and invasion. Cancer Research. 2008, 68(13):5267-5272. 

  72.Hall MD, Okabe M, Shen, DW, Liang, XJ, and Gottesman, MM. The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annual Review of Pharmacology and Toxicology. 200848: 495-535. 

  73.Ngo.T.B*, Peng T., *, Liang X.J *., Akeju O., Pastorino S., Zhang W., Fine H.A., Maric D., Wen P.Y.,  Girolami U.D., Black P.M., Wu W.,  Shen R.F., Kang D.W., and Park J.K. The 1p encoded protein stathmin modulates the response of malignant gliomas to nitrosoureas. Journal of National Cancer Institute. 2007, 99: 639-652.  

  74.Liang, X. J., Mukherjee, S., Shen, D. W., Maxfield, F. R. and Gottesman, M. M. Endocytic Recycling Compartments Altered in Cisplatin-Resistant Cancer Cells . Cancer Research. 2006, 66 (4): Feb 15; 2346-2353.  

  75.Liang, X. J., Shen, D. W., Chen G. K., Wincovitch S. M., Garfield, S., and Gottesman, M. M. Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum.  Journal of Cellular Physiology. 2005, 202 (3): 635-641. 

  76.Liang, X.J, Shen, D.W, and Gottesman, M.M. Down-regulation and altered localization of g-catenin in cisplatin-resistant adenocarcinoma cells.  Molecular Pharmacology. 2004 65 (5): 1217-1224.  

  77.Liang, X.J, Shen, D.W, and Gottesman, M.M. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells.  Journal of Inorganic Biochemistry. 2004 (98) 1599-1606. 

  78.Liang, X.J, Yin, J.J., Zhou, J.W., Wang, P. C., Taylor, B., Cardarelli, C., Kozar, M, Forte, R., Aszalos, A. and Gottesman, M. M. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells.  Experimental Cell Research. 2004, 293: 283-291. 

  79.Liang, X. J., Shen, D. W., Garfield, S., and Gottesman, M. M.  Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistanct cancer cell lines.  Cancer Research. 2003, 63: 5909-5916.   

  Book Chapters: 

  1.Gottesman, M.M., Hall, M.D., Liang, X.J., and Shen, D.W.: Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. In Bonetti, A. Leone, R. Muggia, F. Howell, S.B. (Eds.): Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. Humana Press, Totowa, New Jersey, 2009, 83-88. 

  2. Liang, X.J., Chen, C.Y., Zhao, Y.L., Wang, P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Multi-Drug Resistance in Cancer Series: Methods in Molecular Biology , Zhou, Jun (Ed.), Humana Publisher, New York, 2010; 596: 467-488. 

  3.Tan, J., Liu, C., Hu, L., Wang, C and Liang, X.J. The State of the Science: a 5-Year Review on the Computer-Aided Design for Global Anti-AIDS Drug Development. HIV-infection - Impact, Awareness and Social Implications of living with HIV/AIDS, Eugenia Barros (Edited), 2011, INTECH open access publisher, ISBN978-953-307-343-9. 2011, 25-46. 

  4.Liang, X.J.  Editing “Nanopharmaceuticals: Potential Application of Nanomaterials. (approx. 800pp) World Scientific Publication Press, New Jersey, 2012. ISBN: 978-981-436-866-7. 

  5.Xue, X., Liang, X.J. Multifunctional Nanoparticles for Theranostics and Imaging. Nanomedicine: Nanostructure Science and Technology 2014, pp 101-115.  

  6.梁兴杰、 杨科妮、李盛亮、王重夕、金叔宾等。第6 纳米辅料的药学应用。阎锡蕴主编 科学出版社。2014. Page  281-336 

  7.Huo, S., Cao, X., Hu, Z. and Liang, X.J. Gold Nanoparticles: A Novel and Promising Avenue for Drug Delivery. Chapter 2 in Section I Nanomaterials for Drug Delivery. Biological and Pharmaceutical Application of Nanomaterials. Polina Prokopovich (eds.). CRC Press, Taylor & Francis Group. Florida. 2015, pp 39-53.  

Community service:
Chinese Society of Biophysics Chinese Pharmaceutical AssociationAmerican Association for Cancer ResearchAmerican Society for Cell BiologyAssociation of the International Union against CancerInternational Society of Nanomedicine

Commitment to research the situation:

1.“International Collaborative Nano-program of China and Finland”, 2008-2010.  2.“973 Program (National Key Science and Technology Plan)” of Chinese Ministry of Science and Technology, 2009-2013 Chief Scientist. 3. National Natural Science Foundation of China (Key Program)2014-2017,  Principal Investigator.  4. “863” program (National Program of Gene Therapy) of Chinese Ministry of Science and Technology, 2012-2016Program Investigator. 5. National Natural Science Foundation of China (National Distinguished Young Scholars Program)2013-2016,  Principal Investigator. 6. Strategic Piority Research Program of Chinese Academy of Sciences, 2013-2017, Chief Scientist of Nanopharmaceutical Program.